GluBio Therapeutics
PrivateLast Round
Strategic
Feb 11, 2026
Total Funding Raised
$122M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
GluBio Therapeutics is a biotechnology company that discovers and develops innovative molecular glue-targeted protein degradation drugs to address unmet medical needs in oncology, autoimmune diseases, and genetic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GluBio Therapeutics Comparables
Compare GluBio Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Plexium | 88% | |
| SEED Therapeutics | 84% | |
| Neomorph | 84% |
GluBio Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Feb 11, 2026 | ||||
| Series A Extension | Aug 1, 2022 | ||||
| Series A | Feb 28, 2022 | ||||
| Seed | Feb 1, 2021 |
Key People
Founding team and executive leadership
GluBio Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hillhouse Investment | Series A |
| Kaitai Capital | Series A, Series A Extension, Seed |
| Legend Capital | Series A |
| E Fund Management | Series A |
| 险峰K2VC | Series A, Seed |
| Lilly Asia Ventures | Series A, Series A Extension |
| Qiming Venture Partners | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 56% MoM.
- Jan 19, 2026
Monthly visitors grew 1574% MoM, from 23 to 385.
GluBio Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about GluBio Therapeutics's valuation, stock price, and market status.
Is GluBio Therapeutics a public or private company?
GluBio Therapeutics is a private company.
What is the current stock price of GluBio Therapeutics?
GluBio Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is GluBio Therapeutics worth (valuation)?
Valuation information for GluBio Therapeutics is not publicly available.
Can I buy GluBio Therapeutics stock?
GluBio Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was GluBio Therapeutics's last funding round?
GluBio Therapeutics's most recent funding round was Strategic on February 11, 2026.
Who are the main investors in GluBio Therapeutics?
Key investors in GluBio Therapeutics include Hillhouse Investment, Qiming Venture Partners.
Will GluBio Therapeutics IPO soon?
No public IPO plans have been announced for GluBio Therapeutics.
How can I track GluBio Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GluBio Therapeutics's secondary market activity and sign up for updates.